Avoiding Drug Substance Patents and Exclusivities

Prodrugs, Deuterated Drugs, and 505(b)(2) Applications

April 14, 2016

Webinar

Join Kurt Karst (Hyman, Phelps & McNamara, P.C.) (coauthor, "The FDA Blog")  and Jeffrey Hovden (Robins Kaplan LLP) (coauthor, Generically Speaking) for a collaborative webinar.

For generic drug companies, the biggest and most expensive challenge to a US product launch is the patent that covers the active pharmaceutical ingredient (“API”). Notoriously, only one such patent has ever been invalidated for obviousness.

We present a primer on strategies for generic companies to get around API patents, using the 505(b)(2) application. This route can enable a generic company to use a prodrug or deuterated drug to avoid the API patent—and brand marketing exclusivities—while still benefiting from brand safety and efficacy data.

We’ll use particular examples to illustrate the pros and cons of this basic strategy, discussing current law and FDA regulations, helping you to plan for and maximize such opportunities.

Related Publications

First Quarter
ANDA Approvals
GENERICally Speaking Spring 2021
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Spring 2021
First Quarter
Generic Launches
GENERICally Speaking Spring 2021
First Quarter
New ANDA Cases
GENERICally Speaking Spring 2021
March 2, 2021
AstraZeneca AB v. Mylan Pharms. Inc.
GENERICally Speaking Spring 2021